Clinical Trial: Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title:

Brief Summary: Congenital Telangiectasia or Coat's disease is an uncommon disorder that involves the growth of blood vessels of the macula. These blood vessels msy extend beneth the retina to produce an area of sub-retinal neovascularization(growth of abnormal blood vessels under the retina which "leak" fluid, causing reduction in vision). Limited forms of treatment are available in managing the neovascularization and its consequences. Anecortave Acetate injection will be considered as an attempt to control the growth of the abnormal blood vessels.

Detailed Summary: After evaluation, the patient will receive an injection of anecortave acetate (15mg) juxtascleral with a special cannula in the study eye. the patient will be contacted via phone on the day following the injection. If problem arises patient has to come back to see the study doctor. if patient is stable, a 3 month follow-up visit will be st-up.if the patient does not show improvement, the patient may be offered either thermal laser or PDT. If patient is stable, on the month 6 visit ,the patient will again receive another injection of anecortave acetate. The succeding follow-up schedule will be followed for a total of 24 months.
Sponsor: Manhattan Eye, Ear & Throat Hospital

Current Primary Outcome: to investigate the use of anecortave acetate in coats's disease [ Time Frame: 24 months ]

Original Primary Outcome:

Current Secondary Outcome: mean change in ETDRS visual acuity , OCT, leakage in FA compared at baseline at month 24. [ Time Frame: 24 months ]

Original Secondary Outcome:

Information By: Manhattan Eye, Ear & Throat Hospital

Dates:
Date Received: September 13, 2005
Date Started: March 2002
Date Completion: March 2007
Last Updated: October 23, 2012
Last Verified: October 2012